Piper Jaffray Downgrades Quidel to Neutral

Dec 19, 2016

NEW YORK (GenomeWeb) – Piper Jaffray has downgraded shares of Quidel to a Neutral rating from Overweight, citing the "limited upside" the company is likely to see in the 2016-2017 flu season.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Featured White Papers

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

May

22

Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Menu